E. Nuti et al. / European Journal of Medicinal Chemistry 62 (2013) 379e394
393
[14] S.S. Glasson, R. Askew, B. Sheppard, B.A. Carito, T. Blanchet, H.L. Ma,
C.R. Flannery, K. Kanki, E. Wang, D. Peluso, Z. Yang, M.K. Majumdar,
E.A. Morris, Characterization of and osteoarthritis susceptibility in ADAMTS-4-
knockout mice, Arthritis Rheum. 50 (2004) 2547e2558.
[15] (a) C. De Savi, A. Pape, Y. Sawyer, D. Milne, C. Davies, J.G. Cumming, A. Ting,
S. Lamont, P.D. Smith, J. Tart, K. Page, P. Moore, Orally active achiral N-
hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5
(aggrecanase-2) for the treatment of osteoarthritis, Bioorg. Med. Chem. Lett.
21 (2011) 3301e3306;
4.9.2. Docking setting
Molecular docking calculations were performed with the aid of
Glide 5.5 in extra-precision (XP) [47,48] mode, using Glidescore for
ligand ranking. A constraint that forced the interaction with the
metal ion was included. For multiple ligand docking experiments,
an output maximum of 5000 ligand poses per docking run with
a limit of 100 poses for each ligand was adopted.
(b) C. De Savi, A. Pape, J.G. Cumming, A. Ting, P.D. Smith, J.N. Burrows, M. Mills,
C. Davies, S. Lamont, D. Milne, C. Cook, P. Moore, Y. Sawyer, S. Gerhardt, The
design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4
for the treatment of osteoarthritis, Bioorg. Med. Chem. Lett. 21 (2011)
1376e1381;
Acknowledgments
This study was supported by the Italian Ministry of University
and Scientific Research (PRIN 2007) and by National Institutes of
Health (NIH) grant AR40994 to Professor Hideaki Nagase.
(c) R.J. Cherney, R. Mo, D.T. Meyer, L. Wang, W. Yao, Z.R. Wasserman, R.Q. Liu,
M.B. Covington, M.D. Tortorella, E.C. Arner, M. Qian, D.D. Christ, J.M. Trzaskos,
R.C. Newton, R.L. Magolda, C.P. Decicco, Potent and selective aggrecanase
inhibitors containing cyclic P1 substituents, Bioorg. Med. Chem. Lett. 13
(2003) 1297e1300.
[16] W. Yao, Z.R. Wasserman, M. Chao, G. Reddy, E. Shi, R.Q. Liu, M.B. Covington,
E.C. Arner, M.A. Pratta, M. Tortorella, R.L. Magolda, R. Newton, M. Qian,
M.D. Ribadeneira, D. Christ, R.R. Wexler, C.P. Decicco, Design and synthesis
of a series of (2R)-N4-hydroxy-2-(3-hydroxybenzyl)-N1-[(1S,2R)-2-hydroxy-
2,3-dihydro-1Hinden-1-yl]butanediamide derivatives as potent, selective,
and orally bioavailable aggrecanase inhibitors, J. Med. Chem. 44 (2001)
3347e3350.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
[17] M.C. Noe, V. Natarajan, S.L. Snow, P.G. Mitchell, L. Lopresti-Morrow,
L.M. Reeves, S.A. Yocum, T.J. Carty, J.A. Barberia, F.J. Sweeney, J.L. Liras,
M. Vaughn, J.R. Hardink, J.M. Hawkins, C. Tokar, Discovery of 3,3-dimethyl-5-
hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13,
Bioorg. Med. Chem. Lett. 15 (2005) 2808e2811.
[18] A. Cappelli, C. Nannicini, S. Valenti, G. Giuliani, M. Anzini, M. Mennuni,
A. Giordani, G. Caselli, L.P. Stasi, F. Makovec, G. Giorgi, S. Vomero, Design,
synthesis, and preliminary biological evaluation of pyrrolo[3,4-c]quinolin-1-
one and oxoisoindoline derivatives as aggrecanase inhibitors, Chem. Med.
Chem. 5 (2010) 739e748.
References
[1] C.G. Helmick, D.T. Felson, R.C. Lawrence, S. Gabriel, R. Hirsch, C. Kent Kwoh,
M.H. Liang, H. Maradit Kremers, M.D. Mayes, P.A. Merkel, S.R. Pillemer,
J.D. Reveille, J.H. Stone, Estimates of the prevalence of arthritis and other
rheumatic conditions in the United States. Part I, Arthritis Rheum. 58 (2008)
15e25.
[2] D.P. Symmons, C.D. Mathers, B.P. fleger, The global burden of osteoarthritis in
the year 2000, GBD 2000 Working Paper, World Health Organisation, Geneva,
[3] M. Fajardo, P.E. Di Cesare, Disease-modifying therapies for osteoarthritis:
current status, Drugs Aging 22 (2005) 141e161.
[4] B.M. Vertel, A. Ratcliffe, Aggrecan, in: R.V. Iozzo (Ed.), Proteoglycans: Struc-
ture, Biology and Molecular Interactions, Marcel Dekker, New York, 2000, pp.
343e377.
[5] M.J. Pond, G. Nuki, Experimentally induced osteoarthritis in the dog, Ann.
Rheum. Dis. 32 (1973) 387e388.
[19] (a) M.G. Bursavich, A.M. Gilbert, S. Lombardi, K.E. Georgiadis, E. Reifenberg,
C.R. Flannery, E.A. Morris, Synthesis and evaluation of aryl thio-
xothiazolidinone inhibitors of ADAMTS-5 (Aggrecanase-2), Bioorg. Med.
Chem. Lett. 17 (2007) 1185e1188;
(b) A.M. Gilbert, M.G. Bursavich, S. Lombardi, K.E. Georgiadis, E. Reifenberg,
C.R.
Flannery,
E.A.
Morris,
5-((1H-pyrazol-4-yl)methylene)-2-
thioxothiazolidin-4-one inhibitors of ADAMTS-5, Bioorg. Med. Chem. Lett.
17 (2007) 1189e1192;
(c) A.M. Gilbert, M.G. Bursavich, S. Lombardi, K.E. Georgiadis, E. Reifenberg,
C.R. Flannery, E.A. Morris, N-((8-Hydroxy-5-substituted-quinolin-7-
yl)(phenyl)methyl)-2-phenyloxy/amino-acetamide inhibitors of ADAMTS-5
(aggrecanase-2), Bioorg. Med. Chem. Lett. 18 (2008) 6454e6457;
(d) V. La Pietra, L. Marinelli, S. Cosconati, F.S. Di Leva, E. Nuti, S. Santamaria,
I. Pugliesi, M. Morelli, F. Casalini, A. Rossello, C. La Motta, S. Taliani, R. Visse,
H. Nagase, F. Da Settimo, E. Novellino, Identification of novel molecular
scaffolds for the design of MMP-13 inhibitors: a first round of lead opti-
mization, Eur. J. Med. Chem. 47 (2012) 143e152.
[6] M.D. Tortorella, T.C. Burn, M.A. Pratta, I. Abbaszade, J.M. Hollis, R. Liu,
S.A. Rosenfeld, R.A. Copeland, C.P. Decicco, R. Wynn, A. Rockwell, F. Yang,
J.L. Duke, K. Solomon, H. George, R. Bruckner, H. Nagase, Y. Itoh, D.M. Ellis,
H. Ross, B.H. Wiswall, K. Murphy, M.C. Hillman Jr., G.F. Hollis, R.C. Newton,
R.L. Magolda, J.M. Trzaskos, E.C. Arner, Purification and cloning of
aggrecanase-1: a member of the ADAMTS family of proteins, Science 284
(1999) 1664e1666.
[7] (a) J.D. Sandy, P.J. Neame, R.E. Boynton, C.R. Flannery, Catabolism of aggrecan
in cartilage explants. Identification of a major cleavage site within the inter-
globular domain, J. Biol. Chem. 266 (1991) 8683e8685;
[20] M. Shiozaki, K. Maeda, T. Miura, M. Kotoku, T. Yamasaki, I. Matsuda, K. Aoki,
K. Yasue, H. Imai, M. Ubukata, A. Suma, M. Yokota, T. Hotta, M. Tanaka, Y. Hase,
J. Haas, A.M. Fryer, E.R. Laird, N.M. Littmann, S.W. Andrews, J.A. Josey,
T. Mimura, Y. Shinozaki, H. Yoshiuchi, T. Inaba, Discovery of (1S,2R,3R)-2,3-
dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly
selective aggrecanase inhibitors, J. Med. Chem. 54 (2011) 2839e2863.
[21] (a) E. Nuti, F. Casalini, S.I. Avramova, S. Santamaria, G. Cercignani, L. Marinelli,
V. La Pietra, E. Novellino, E. Orlandini, S. Nencetti, T. Tuccinardi, A. Martinelli,
N.H. Lim, R. Visse, H. Nagase, A. Rossello, N-O-isopropyl sulfonamido-based
hydroxamates: design, synthesis and biological evaluation of selective ma-
trix metalloproteinase-13 inhibitors as potential therapeutic agents for
osteoarthritis, J. Med. Chem. 52 (2009) 4757e4773;
(b) C.B. Little, C.T. Meeker, S.B. Golub, K.E. Lawlor, P.J. Farmer, S.M. Smith,
A.J. Fosang, Blocking aggrecanase cleavage in the aggrecan interglobular
domain abrogates cartilage erosion and promotes cartilage repair, J. Clin.
Invest. 117 (2007) 1627e1636.
[8] L.S. Lohmander, P.J. Neame, J.D. Sandy, The structure of aggrecan fragments in
human synovial fluid. Evidence that aggrecanase mediates cartilage degra-
dation in inflammatory joint disease, joint injury, and osteoarthritis, Arthritis
Rheum. 36 (1993) 1214e1222.
[9] M.D. Tortorella, A.M. Malfait, C. Deccico, E. Arner, The role of ADAM-TS4
(aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage deg-
radation, Osteoarthr. Cartil. 9 (2001) 539e552.
(b) S. Santamaria, E. Nuti, G. Cercignani, L. Marinelli, V. La Pietra, E. Novellino,
A. Rossello, N-O-Isopropyl sulfonamido-based hydroxamates: kinetic char-
acterisation of a series of MMP-12/MMP-13 dual target inhibitors, Biochem.
Pharmacol. 84 (2012) 813e820.
[10] C. Gendron, M. Kashiwagi, N.H. Lim, J.J. Enghild, I.B. Thogersen, C. Hughes,
B. Caterson, H. Nagase, Proteolytic activities of human ADAMTS-5. Com-
parative studies with ADAMTS-4, J. Biol. Chem. 282 (2007) 18294e18306.
[11] S.S. Glasson, R. Askew, B. Sheppard, B. Carito, T. Blanchet, H.L. Ma,
C.R. Flannery, D. Peluso, Z. Yang, M.K. Majumdar, E.A. Morris, Deletion of
active ADAMTS5 prevents cartilage degradation in a murine model of osteo-
arthritis, Nature 434 (2005) 644e648.
[22] (a) J.T. Peterson, The importance of estimating the therapeutic index in the
development of matrix metalloproteinase inhibitors, Cardiovasc. Res. 69
(2006) 677e687;
(b) D.P. Becker, T.E. Barta, L.J. Bedell, T.L. Boehm, B.R. Bond, J. Carroll,
C.P. Carron, G.A. Decrescenzo, A.M. Easton, J.N. Freskos, C.L. Funckes-Shippy,
M. Heron, S. Hockerman, C.P. Howard, J.R. Kiefer, M.H. Li, K.J. Mathis,
J.J. McDonald, P.P. Mehta, G.E. Munie, T. Sunyer, C.A. Swearingen, C.I. Villamil,
[12] H. Stanton, F.M. Rogerson, C.J. East, S.B. Golub, K.E. Lawlor, C.T. Meeker,
C.B. Little, K. Last, P.J. Farmer, I.K. Campbell, A.M. Fourie, A.J. Fosang, ADAMTS-
5 is the major aggrecanase in mouse cartilage in vivo and in vitro, Nature 434
(2005) 648e652.
[13] (a) A.M. Malfait, J. Ritchie, A.S. Gil, J.S. Austin, J. Hartke, W. Qin, M.D. Tortorella,
J.S. Mogil, ADAMTS-5 deficient mice do not develop mechanical allodynia
associated with osteoarthritis following medial meniscal destabilization,
Osteoarthr. Cartil. 18 (2010) 572e580;
D. Welsch, J.M. Williams, Y. Yu, J. Yao, Orally active MMP-1 sparing
a-tetra-
hydropyranyl and -piperidinyl sulfone matrix metalloproteinase (MMP) in-
a
hibitors with efficacy in cancer, arthritis, and cardiovascular disease, J. Med.
Chem. 53 (2010) 6653e6680.
[23] A. Rossello, E. Nuti, E. Orlandini, P. Carelli, S. Rapposelli, M. Macchia,
F. Minutolo, L. Carbonaro, A. Albini, R. Benelli, G. Cercignani, G. Murphy,
A. Balsamo, New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as
selective inhibitors of gelatinase A (MMP-2), Bioorg. Med. Chem. 12 (2004)
2441e2450.
(b) J. Li, W. Anemaet, M.A. Diaz, S. Buchanan, M. Tortorella, A.M. Malfait,
K. Mikecz, J.D. Sandy, A. Plaas, Knockout of ADAMTS5 does not eliminate
cartilage aggrecanase activity but abrogates joint fibrosis and promotes car-
tilage aggrecan deposition in murine osteoarthritis models, J. Orthop. Res. 29
(2011) 516e522.